Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients with inadequate efficacy response to prior therapy: 4-year follow-up of CARE-MS II

被引：0
|
作者：
Arroyo Gonzalez, R. [1 ]
Moreau, T. [2 ]
Cohen, J. A. [3 ]
Giovannoni, G. [4 ]
Margolin, D. H. [5 ]
Kasten, L. [6 ]
Havrdova, E. [7 ]
机构：
[1] Hosp Clin San Carlos, Madrid, Spain
[2] Burgundy Univ, Dijon Univ Hosp, Dijon, France
[3] Cleveland Clin, Cleveland, OH 44106 USA
[4] Queen Mary Univ London, Barts & London Sch Med, London, England
[5] Genzyme, Cambridge, MA USA
[6] PROMETRIKA LLC, Cambridge, MA USA
[7] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2015年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
F2070
引用
收藏
页码：614 / 614
页数：1
相关论文
共 50 条
  • [1] Alemtuzumab improves quality of life in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: 3-year follow-up of CARE-MS II
    Moreau, T.
    Margolin, D. H.
    Kasten, L.
    Singer, B.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 86 - 86
  • [2] Alemtuzumab improves MRI outcomes in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy: three-year follow-up of CARE-MS II
    Fisher, E.
    Barkhof, F.
    Cohen, J. A.
    Fox, E. J.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 113 - 114
  • [3] Patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy demonstrate durable improvements in clinical outcomes with alemtuzumab-5-year follow-up of CARE-MS II
    Alroughani, Raed
    Al Jumah, Mohamed
    Arnold, Douglas L.
    Hartung, Hans-Peter
    Havrdova, Eva
    Inshasi, Jihad Said
    Margolin, David H.
    Kasten, Linda
    Compston, D. Alasdair S.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (06) : NP9 - NP9
  • [4] Durable efficacy of alemtuzumab in CARE-MS II patients with highly active relapsing-remitting multiple sclerosis: 4-year outcomes
    Krieger, S.
    Freedman, M. S.
    Moreau, T.
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Kasten, L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 573 - 573
  • [5] Efficacy and safety of alemtuzumab in patients with relapsing-remitting MS who relapsed on prior therapy: four-year follow-up of the CARE-MS II study
    Hartung, H-P
    Arnold, D. L.
    Cohen, J. A.
    Coles, A. J.
    Fox, E. J.
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Oyuela, P.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 85 - 86
  • [6] Durable Efficacy of Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients Who Participated in the CARE-MS Studies: Three Year Follow-Up
    Fox, Edward
    Arnold, Douglas
    Cohen, Jeffrey
    Coles, Alasdair
    Confavreux, Christian
    Hartung, Hans
    Havrdova, Eva
    Selmaj, Krzysztof
    Weiner, Howard
    Twyman, Cary
    Vladic, Anton
    Margolin, David
    Oyuela, Pedro
    Panzara, Michael
    Compston, Alastair
    NEUROLOGY, 2013, 80
  • [7] Efficacy and Safety of Alemtuzumab in Patients With Relapsing-Remitting MS Who Relapsed on Prior Therapy: Four-Year Follow-up of the CARE-MS II Study
    Vucic, S.
    Coles, A. J.
    Arnold, D. L.
    Hartung, H-P
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Oyuela, P.
    Panzara, M. A.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (06) : 821 - 821
  • [8] Safety of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS II)
    Havrdova, E.
    Arnold, D. L.
    Cohen, J.
    Coles, A. J.
    Confavreux, C.
    Fox, E. J.
    Hartung, H. -P.
    Selmaj, K.
    Weiner, H.
    Miller, T.
    Twyman, C. L.
    Lake, S. L.
    Margolin, D. H.
    Panzara, M.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 235 - 235
  • [9] Efficacy of alemtuzumab is durable over 6 years in patients with active relapsing-remitting multiple sclerosis and an inadequate response to prior therapy in the absence of continuous treatment (CARE-MS II)
    Fox, E. J.
    Alroughani, R.
    Brassat, D.
    Broadley, S.
    Cohen, J. A.
    Hartung, H. -P.
    Havrdova, E.
    Oreja-Guevara, C.
    Selmaj, K. W.
    Singer, B.
    Vermersch, P.
    Wray, S.
    Margolin, D. H.
    Thangavelu, K.
    Chirieac, M.
    Coles, A. J.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 596 - 597
  • [10] Efficacy of Alemtuzumab Is Durable Over 6 Years in Patients with Active Relapsing-Remitting Multiple Sclerosis and an Inadequate Response to Prior Therapy in the Absence of Continuous Treatment (CARE-MS II)
    Broadley, S.
    Alroughani, R.
    Brassat, D.
    Hartung, H-P
    Oreja-Guevara, C.
    Selmaj, K. W.
    Singer, B.
    Vermersch, P.
    Wray, S.
    Margolin, D. H.
    Thangavelu, K.
    Chirieac, M.
    Havrdova, E.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (02) : 338 - 339
12345